Orthoclone OKT3 Disease Interactions
There are 4 disease interactions with Orthoclone OKT3 (muromonab-cd3).
Muromonab-CD3 (applies to Orthoclone OKT3) cardiovascular dysfunction
Major Potential Hazard, High plausibility. Applicable conditions: Congestive Heart Failure, Arrhythmias, Ischemic Heart Disease
The use of muromonab-CD3 is contraindicated in patients with uncompensated heart failure. Cardiovascular collapse, cardiac arrest, severe hypotension, shock, left ventricular dysfunction, and arrhythmias have occurred in patients administered muromonab-CD3. Patients with cardiovascular impairments are at increased risk for more serious cardiorespiratory complications (respiratory arrest, failure, distress, and/or cardiovascular collapse, cardiac arrest, angina, or myocardial infarction) from muromonab-CD3-associated Cytokine Release Syndrome.
References
- Hollenbeck M, Westhoff A, Bach D, Grabensee B, Kolvenbach R, Kniemeyer HW "Doppler sonography and renal graft vessel thromboses after OKT3 treatment." Lancet 340 (1992): 619-20
- Abramowicz D, Pradier O, Marchant A, Florquin S, De Pauw L, Vereerstraeten P, Kinnaert P, Vanherweghem JL, Goldman M "Induction of thromboses within renal grafts by high-dose prophylactic OKT3." Lancet 339 (1992): 777-8
- Spieker C, Zidek W, Barenbrock M, Wieneke R, Buchholz B, Rahn KH "Acute hypertension after renal allograft rejection therapy with OKT3 monoclonal antibody." J Int Med Res 19 (1991): 419-23
- Pradier O, Marchant A, Abramowicz D, De Pauw L, Vereerstraeten P, Kinnaert P, Vanherweghem JL, Capel P, Goldman M "Procoagulant effect of the OKT3 monoclonal antibody: involvement of tumor necrosis factor." Kidney Int 42 (1992): 1124-9
- Costanzo-Nordin MR "Cardiopulmonary effects of OKT3: determinants of hypotension, pulmonary edema, and cardiac dysfunction." Transplant Proc 25 (1993): 21-4
- Spieker C, Barenbrock M, Buchholz B, Heidenreich S, Zidek W "Cardiovascular effects of ATG and OKT3 in renal allograft recipients." Transplant Proc 24 (1992): 2594-5
- "Product Information. Orthoclone OKT3 (muromonab-CD3)." Ortho McNeil Pharmaceutical
- Sgro C "Side-effects of a monoclonal antibody, muromonab CD3 orthoclone OKT3: bibliographic review." Toxicology 105 (1995): 23-9
Muromonab-CD3 (applies to Orthoclone OKT3) neuro/psychiatric dysfunction
Major Potential Hazard, High plausibility. Applicable conditions: Cerebral Vascular Disorder, Seizures, Head Injury
The use of muromonab-CD3 is contraindicated in patients with or predisposed to seizures. Seizures, cerebral edema, confusion, auditory/visual hallucinations, mental status changes, psychosis, mania, lethargy, stupor, or coma have occurred in patients administered muromonab-CD3. Patient with CNS disorders, cerebrovascular disease, neurological disturbances are at increased risk for neuro/psychiatric events.
References
- Coleman AE, Norman DJ "OKT3 Encephalopathy." Ann Neurol 28 (1990): 837
- Capone PM, Cohen ME "Seizures and cerebritis associated with administration of OKT3." Pediatr Neurol 7 (1991): 299-301
- Shihab FS, Barry JM, Norman DJ "Encephalopathy following the use of OKT3 in renal allograft transplantation." Transplant Proc 25 (1993): 31-4
- Jeffrey RF, Johnson MH, Bamford JM, Giles GR, Brownjohn AM, Will EJ "Prolonged neurological disability following OKT3 therapy for acute renal transplant rejection." Transplantation 55 (1993): 677-9
- "Product Information. Orthoclone OKT3 (muromonab-CD3)." Ortho McNeil Pharmaceutical
- Kehinde EO, Scriven SD, Feehally J, Veitch PS, Varty K, Bell PRF "Adverse effects of OKT3 therapy: increased risk with impaired renal function." Transplant Proc 26 (1994): 1945-7
- Sgro C "Side-effects of a monoclonal antibody, muromonab CD3 orthoclone OKT3: bibliographic review." Toxicology 105 (1995): 23-9
Muromonab-CD3 (applies to Orthoclone OKT3) volume overload
Major Potential Hazard, High plausibility. Applicable conditions: Fluid Retention
The use of muromonab-CD3 is contraindicated in patients with fluid overload as evidences by chest X-ray or a 3% or more weight gain in the week prior to muromonab-CD3 therapy. Patients with fluid overload are at increased risk for more serious cardiopulmonary complications (respiratory arrest, failure, distress, and/or cardiovascular collapse, cardiac arrest, angina, or myocardial infarction) from muromonab-CD3-associated Cytokine Release Syndrome.
References
- Todd PA, Brogden RN "Muromonab CD3. A review of its pharmacology and therapeutic potential." Drugs 37 (1989): 871-99
- "Product Information. Orthoclone OKT3 (muromonab-CD3)." Ortho McNeil Pharmaceutical
- Sgro C "Side-effects of a monoclonal antibody, muromonab CD3 orthoclone OKT3: bibliographic review." Toxicology 105 (1995): 23-9
Muromonab-CD3 (applies to Orthoclone OKT3) fever
Moderate Potential Hazard, Moderate plausibility.
Muromonab-CD3 should not be administered in the presence of a body temperature of 100 degrees F (38.7 degrees C) or greater. Spiking fever (to 107 degrees F) associated with the Cytokine Release Syndrome have occurred. Antipyretics may be administered to reduce body temperature in this setting.
References
- Shield CF II, Kahana L, Pirsch J, et al. "Use of indomethacin to minimize the adverse reactions associated with orthoclone OKT3 treatment of kidney allograft rejection." Transplantation 54 (1992): 164-6
- Todd PA, Brogden RN "Muromonab CD3. A review of its pharmacology and therapeutic potential." Drugs 37 (1989): 871-99
- Agarwal RK, Ostaszewski ML, Feld LG, Springate JE, Moxey-Mims MM, O'Neil KM "Tumor necrosis factor and interleukin-6 in cerebrospinal fluid of a patient with recurrent adverse central nervous system events following OKT3." Transplant Proc 25 (1993): 2143-4
- Radhakrishnan J, Cohen DJ "Cytokine-release syndrome: general risk-factor modification-- preparation of high-risk patients for use of OKT3." Transplant Proc 25 (1993): 60-2
- First MR, Schroeder TJ, Hariharan S, Weiskittel P "Reduction of the initial febrile response to OKT3 with indomethacin." Transplant Proc 25 (1993): 52-4
- Chatenoud L "OKT3-induced cytokine-release syndrome: prevention effect of anti-tumor necrosis factor monoclonal antibody." Transplant Proc 25 (1993): 47-51
- Doutrelepont JM, Abramowicz D, Borre B, Lemoine A, De Pauw L, Kinnaert P, Vereerstraeten P, Vanherweghem JL, Goldman M "Prophylactic OKT3: practical considerations for the prevention of first-dose reactions." Transplant Proc 25 (1993): 45-6
- Norman DJ, Kimball JA, Barry JM "Cytokine-release syndrome: differences between high and low doses of OKT3." Transplant Proc 25 (1993): 35-8
- Jeyarajah DR, Thistlethwaite JR, Jr "General aspects of cytokine-release syndrome: timing and incidence of symptoms." Transplant Proc 25 (1993): 16-20
- Shihab F, Barry JM, Bennett WM, Meyer MM, Norman DJ "Cytokine-related encephalopathy induced by OKT3: incidence and predisposing factors." Transplant Proc 25 (1993): 564-5
- First MR, Schroeder TJ, Hariharan S, Alexander JW, Weiskittel P "The effect of indomethacin on the febrile response following OKT3 therapy." Transplantation 53 (1992): 91-4
- Hall KA, Dole EJ, Hunter GC, Zukoski CF, Putnam CW "Hyperpyrexia-related ventricular tachycardia during OKT3 induction therapy." Transplantation 54 (1992): 1112-3
- "Product Information. Orthoclone OKT3 (muromonab-CD3)." Ortho McNeil Pharmaceutical
- Devault GA, Kohan DE, Nelson EW, Holman JM "The effects of oral pentoxifylline on the cytokine release syndrome during inductive OKT3." Transplantation 57 (1994): 532-40
- Sgro C "Side-effects of a monoclonal antibody, muromonab CD3 orthoclone OKT3: bibliographic review." Toxicology 105 (1995): 23-9
Orthoclone OKT3 drug interactions
There are 163 drug interactions with Orthoclone OKT3 (muromonab-cd3).
More about Orthoclone OKT3 (muromonab-cd3)
- Orthoclone OKT3 consumer information
- Check interactions
- Compare alternatives
- Side effects
- Dosage information
- During pregnancy
- Drug class: selective immunosuppressants
Related treatment guides
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.